RecruitingNCT05145478

CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

CTA_IIT_CRUSH PAD: Real-world Outcomes Following Use of the Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions


Sponsor

Yale University

Enrollment

50 participants

Start Date

Dec 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The primary goal of the study is to obtain effect size data on the use of Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with peripheral artery disease for a series of endpoints, including target lesion revascularization and health status, to enable future planning of comparative effectiveness research.


Eligibility

Min Age: 18 Years

Inclusion Criteria9

  • Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4, 5, or 6 of the target limbs
  • Subject is a suitable candidate for angiography and endovascular intervention per the latest clinical guidelines
  • Patient is scheduled to undergo treatment with Shockwave Intravascular Lithotripsy (IVL) technology followed by standard of care treatment with DCB, BMS, DES at the physician's discretion.
  • Target lesion that is located in a native, de novo common femoral artery
  • Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate.
  • Target lesion is ≥70% stenosis by investigator via visual estimate.
  • Target lesion length is ≤50mm for lesions 70-99% stenosed. Target lesion can be all or part of the 50mm treated zone.
  • Chronic total occlusion, lesion length is ≤50mm of the total ≤50 mm target lesion.
  • Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending \> 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is \<50mm in length.

Exclusion Criteria8

  • Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Shockwave Medical Peripheral Lithoplasty® System as per Instructions for Use (IFU) or investigator's opinion.
  • Subject is already enrolled in other investigational (interventional) studies that would interfere with study endpoints.
  • Cognitive impairment as documented in medical records
  • Not speaking English or Spanish
  • Currently a prisoner
  • Pregnancy or nursing
  • Estimated survival less than 12 months at the time of screening
  • Prior history of CFA endarterectomy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEShockwave Intravascular Lithotripsy (IVL)

Eligible patients with atherosclerotic lesions in the femoral artery who either have claudication or critical limb ischemia will receive endovascular treatment in addition to be treated with Shockwave Intravascular Lithotripsy (IVL) technology.


Locations(2)

Yale New Haven Health

New Haven, Connecticut, United States

The Miriam Hospital

Providence, Rhode Island, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05145478


Related Trials